Universal reference book for medicines
Product name: BUTADION (BUTADION)

Active substance: phenylbutazone

Type: NSAID for external use

Manufacturer: GEDEON RICHTER (Hungary)
Composition, form of production and packaging
?
Ointment for external use 5% white, homogeneous, with a weak specific odor.
1 tuba

phenylbutazone 1 g

Auxiliary substances: methyl parahydroxybenzoate 0.04 g, carmellose sodium 0.13 g, colloidal colloidal silicon 0.89 g, polysorbate 60-1 g, glycerol 85% 1.4 g, propylene glycol 2.4 g, liquid paraffin 6 g, water 7.14 g.

20 g - aluminum tubes (1) - packs of cardboard.

INSTRUCTION FOR THE SPECIALIST.

Description of the drug approved by the manufacturer for the printed edition of 2016.

PHARMACHOLOGIC EFFECT

Nonsteroidal anti-inflammatory drug, has anti-inflammatory and analgesic effect.
Indiscriminately inhibits the activity of cyclooxygenases (COX-1 and COX-2) and inhibits the synthesis of prostaglandins.
Phenylbutazone inhibits the synthesis of ATP-dependent mucopolysaccharides.

Butadion is used to eliminate the pain syndrome and reduce the swelling associated with the inflammatory process.
When topical application causes weakening or disappearance of pain in joints at rest and during movement. Reduces the morning stiffness and swelling of the joints, contributes to an increase in the volume of movements.
PHARMACOKINETICS

At application system absorption does not exceed 5%.

Phenylbutazone is metabolized in the liver, excreted in the form of metabolites mainly by the kidneys and about 1/4 - through the intestine.
Elimination time from blood plasma is long (an average of 70 hours, in elderly people up to 105 hours).
INDICATIONS

- Post-traumatic inflammation of soft tissues and joints, for example, as a result of stretching, overstrain and bruises;

- rheumatic diseases of soft tissues (tendovaginitis, bursitis, lesion of periarticular tissues);

- muscular pain of rheumatic and non-rheumatic origin;

- pain syndrome and puffiness associated with diseases of the muscles and joints;

- rheumatoid arthritis;

- osteoarthrosis;

- radiculitis;

- Lumbago;

- sciatica.

DOSING MODE

The drug is used externally.

Adults and children over 14 years of age: the drug is applied with a thin layer (a strip 2-3 cm long) over the inflammation focus, without rubbing, 2-3 times / day.The course of treatment is 7-10 days.
After 10 days of use, consult a physician.
In elderly patients, there is no need for a special mode of administration.

SIDE EFFECT

Local reactions: eczema, photosensitivity, contact dermatitis (itching, redness, swelling of the treated area of ​​the skin, papules, vesicles, peeling).

Allergic reactions: urticaria, angioedema, bronchospasm, generalized skin rash.

CONTRAINDICATIONS

- data on an attack of bronchial obstruction, allergic rhinitis, hives after taking acetylsalicylic acid or another NSAID in history;

- violation of the integrity of the skin at the site of the intended application;

- joint use with other drugs containing phenylbutazone;

- I and III trimesters of pregnancy;

- lactation period;

- children's age till 14 years;

- hypersensitivity to phenylbutazone or other components of the drug, to acetylsalicylic acid and other NSAIDs.

PREGNANCY AND LACTATION

The drug is contraindicated in the I and III trimesters of pregnancy because of the possibility of impaired development of the fetus.
In the second trimester of pregnancy, the use of Butadione is possible only if the intended benefit to the mother exceeds the potential risk to the fetus.
If it is necessary to use the drug during lactation it is recommended to stop breastfeeding.

APPLICATION FOR CHILDREN

The drug is contraindicated in children under the age of 14 years.

APPLICATION IN ELDERLY PATIENTS

There is no need for a special regimen for elderly patients.

SPECIAL INSTRUCTIONS

If skin reddening occurs, therapy should be discontinued.

Ointment should be applied only to intact skin, avoiding getting on open wounds.
After applying, do not apply an occlusive dressing.
Do not allow the drug to enter the eyes and mucous membranes.

The drug should not be used to treat deep vein thrombophlebitis of the extremities.

To prevent photosensitivity, protect the skin from direct sunlight.

When combined with other dosage forms of Butadione, the maximum daily dose of the drug should be taken into account.

Impact on the ability to drive vehicles and manage mechanisms

Data on the impact of Butadia on the ability to drive and engage in other activities that require concentration and speed of psychomotor reactions are not provided.

OVERDOSE

Extremely low absorption of active components of the drug with external application makes an overdose almost impossible.

Symptoms: with the accidental ingestion of large amounts of ointment (more than 20 g), the occurrence of systemic adverse reactions, characteristic of NSAIDs.

Treatment: it is necessary to wash the stomach, taking activated charcoal.

DRUG INTERACTION

Clinically significant interaction of Butadion with other drugs has not been established.

It should avoid joint use of the drug Butadione with other NSAIDs.

Butadione can enhance the effect of drugs that cause photosensitivity.

TERMS OF RELEASE FROM PHARMACY

The drug is approved for use as a means of OTC.

TERMS AND CONDITIONS OF STORAGE

The drug should be stored out of reach of children at a temperature of 8 ° to 15 ° C.
Shelf life - 5 years.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!